XML 68 R56.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting                
Number of operating segments | segment             1  
Number of reportable segments | segment             1  
Revenue $ 14,544     $ 15,425     $ 38,701 $ 46,641
Cost of product revenue 1,774     1,561     4,980 4,396
Research & Development                
Stock-based compensation 11,691     6,641     31,825 25,912
Depreciation             3,076 2,835
Interest income 3,729     5,653     11,012 15,611
Interest expense (3,002)     (3,224)     (9,003) (10,471)
Loss from debt extinguishment               (27,950)
Net Income (Loss) (69,418) $ (67,814) $ (64,053) (36,493) $ (43,777) $ (64,848) (201,285) (145,118)
Single Reportable Segment                
Segment Reporting                
Revenue 14,544     15,425     38,701 46,641
Cost of product revenue 1,774     1,561     4,980 4,396
Research & Development                
Direct program expenses, AXPAXLI for wet AMD 34,707     17,017     92,893 35,263
Direct program expenses, Other clinical and preclinical programs 1,224     1,184     3,307 6,750
Unallocated expenses, Personnel costs 9,136     7,551     27,825 22,168
Unallocated expenses, All other costs 1,632     6,365     5,986 8,815
Selling and marketing 11,721     9,601     36,972 27,997
General and administrative 8,563     8,832     26,864 28,294
Facilities 1,722     1,713     5,230 5,416
Stock-based compensation 11,691     6,641     31,825 25,912
Depreciation 1,072     958     3,076 2,835
Interest income 3,729     5,653     11,012 15,611
Interest expense (3,002)     (3,224)     (9,003) (10,471)
Loss from debt extinguishment               (27,950)
Other non-operating items (1,447)     7,076     (3,037) (1,103)
Net Income (Loss) $ (69,418)     $ (36,493)     $ (201,285) $ (145,118)